Structured evidence table for Inositol Sleep Latency Randomized Trial, generated from 2 reusable source documents in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Inositol Sleep Latency Randomized Trial | These disturbances occur despite adequate opportunity and conditions for sleep [], and they result in general dissatisfaction with sleep quality and various daytime impairments. | 3 | Żełabowski Kacper (2025) | The Efficacy of Melatonergic Receptor Agonists Used in Clinical Practice in Insomnia Treatment: Melatonin, Tasimelteon, Ramelteon, Agomelatine, and Selected Herbs |
| Inositol Sleep Latency Randomized Trial | Individuals reporting nighttime symptoms without associated daytime dysfunction are not classified as having clinical insomnia [,]. | 3 | Żełabowski Kacper (2025) | The Efficacy of Melatonergic Receptor Agonists Used in Clinical Practice in Insomnia Treatment: Melatonin, Tasimelteon, Ramelteon, Agomelatine, and Selected Herbs |
| Inositol Sleep Latency Randomized Trial | Studies have demonstrated a direct correlation between inadequate sleep and an increased risk of developing metabolic diseases, such as diabetes, obesity, hypertension, cardiovascular disease, and depression [,,]. | 3 | Żełabowski Kacper (2025) | The Efficacy of Melatonergic Receptor Agonists Used in Clinical Practice in Insomnia Treatment: Melatonin, Tasimelteon, Ramelteon, Agomelatine, and Selected Herbs |
| Inositol Sleep Latency Randomized Trial | 1 2 2 3 4 3 5 6 6 4 6 The etymology of the term “insomnia” derives from Latin, combining “in” meaning “not” and “somnus,” meaning “sleep” []. | 3 | Żełabowski Kacper (2025) | The Efficacy of Melatonergic Receptor Agonists Used in Clinical Practice in Insomnia Treatment: Melatonin, Tasimelteon, Ramelteon, Agomelatine, and Selected Herbs |
| Inositol Sleep Latency Randomized Trial | Failure to meet the recommended 7-9 hours of restful sleep per night is known to increase the risk of several health conditions, reason why regular and adequate sleep should be seen as a priority instead of an unnecessary commodity easily traded as required by the commitments of our busy lives. | 4 | Conti F (2026) | Dietary Protocols to Promote and Improve Restful Sleep: A Narrative Review. |
| Inositol Sleep Latency Randomized Trial | While both the quantity and the quality of sleep can be largely improved with relatively straightforward practices dictated by good sleep hygiene, emerging research suggests that dietary and supplementation protocols focused on certain foods, nutrients, and biochemical compounds with sleep-promoting properties can act as subsidiary sleep aids in complementing these behavioral changes. | 4 | Conti F (2026) | Dietary Protocols to Promote and Improve Restful Sleep: A Narrative Review. |
| Inositol Sleep Latency Randomized Trial | The scope of this narrative review is to summarize the available evidence on the potential benefits of selected nutraceuticals in the context of circadian rhythm and sleep disturbances, namely melatonin, magnesium, omega-3 fatty acids, tart cherry juice, kiwifruit, apigenin, valerian root, L-theanine, glycine, ashwagandha, myoinositol, Rhodiola rosea, and phosphatidylserine. | 4 | Conti F (2026) | Dietary Protocols to Promote and Improve Restful Sleep: A Narrative Review. |
| Inositol Sleep Latency Randomized Trial | Humans spend approximately one third of their life asleep but, as counterintuitive as it may sound, sleep is far from being a quiet state of inactivity. | 4 | Conti F (2026) | Dietary Protocols to Promote and Improve Restful Sleep: A Narrative Review. |
Source documents